Document is current
Any future updates will be listed below
-
Authors
Kimman, Thomas
Cuenca, Marta https://orcid.org/0000-0003-2261-7792
Tieland, Ralph G.
Rockx-Brouwer, Dedeke
Janssen, Jasmijn
Motais, Benjamin
Slomp, Anne
Pleijte, Corine
Heijhuurs, Sabine
Meringa, Angelo D.
Boschloo, Wendy https://orcid.org/0000-0002-1599-1391
Bosma, Douwe MT https://orcid.org/0000-0002-3500-8649
Kroos, Sanne https://orcid.org/0000-0001-8900-1285
lo Presti, Vania
Sluijter, Joost P. G. https://orcid.org/0000-0003-2088-9102
Nierkens, Stefan
Bovenschen, Niels https://orcid.org/0000-0002-8526-4456
Kuball, Jürgen https://orcid.org/0000-0002-3914-7806
van Mil, Alain
Minnema, Monique C.
Sebestyén, Zsolt https://orcid.org/0000-0001-6184-7676
Peperzak, Victor https://orcid.org/0000-0002-9011-3820
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (11270, 13058, 15595, 14459)
- License Information
-
More Information
Article History
Received: 21 November 2023
Accepted: 6 May 2025
First Online: 19 May 2025
Competing interests
: V.P. received royalty payments related to venetoclax. V.P., Z.S., and T.K. are inventors on a patent for improving cytotoxicity of gene engineered T and NK cells. M.C.M. received research funding from Beigene, Janssen Cilag, Speakers fee from Janssen Cilag, Siemens, and Pfizer, and Consultancy fee from Janssen Cilag, Pfizer, BMS, and Hospitality Janssen Cilag, Beigene, all paid to institution. Z.S. and J.K. are inventors on different patents for γδ T-cell receptor sequences, recognition mechanisms, and isolation strategies. J.K. is the founder and shareholder of Gadeta Founders BV. The remaining authors declare no competing interests.
